Findings
Clinical Evaluation Components: Valid Clinical Association: Demonstrates that the SaMD’s outputs are clinically meaningful and relevant to the intended healthcare condition. Analytical Validation: Confirms that the SaMD processes input data accurately and reliably to produce the intended output. Clinical Validation: Assesses whether the SaMD achieves its intended purpose in the target population.
Lifecycle Management: Clinical evaluation is an ongoing process that spans pre-market development and post-market monitoring.
Post-market data collection supports continuous improvement, including refining or expanding the SaMD’s intended use.
Risk-Based Approach: The depth and independence of clinical evaluation depend on the SaMD’s risk categorization, with higher-risk categories requiring more rigorous oversight and validation.
Real-World Evidence: SaMD manufacturers are encouraged to use real-world performance data for iterative learning, ensuring alignment with evolving clinical needs.
Independent Review: High-risk SaMD (e.g., those used for critical diagnoses or treatments) benefit from independent evaluation to manage bias and validate clinical evidence.

Recommendations
Pre-Market: Generate evidence through clinical trials, literature reviews, and secondary data analysis to demonstrate valid clinical association and analytical validation.
Use a risk-based framework to determine the rigor of clinical evaluation.
Post-Market: Leverage real-world performance data for continuous improvement and risk management.
Monitor safety, effectiveness, and user interactions, adapting the SaMD definition statement as needed.
Regulatory Submissions: Provide a clear SaMD definition statement, including intended use and core functionality.
Include comprehensive validation data, particularly for high-risk SaMD.
Independent Review: Engage third-party reviewers for high-risk SaMD to enhance transparency and confidence in clinical evaluation.
Quality Management: Integrate clinical evaluation activities into the organization’s quality management system to ensure consistency and compliance.

Regulatory Considerations
SaMD manufacturers must comply with jurisdiction-specific pre-market and post-market requirements, such as informed consent for clinical trials and regulatory submissions for significant changes.
Changes to the SaMD’s intended use or performance measures, based on post-market data, may necessitate updated regulatory approvals.
Independent review requirements vary by jurisdiction but are critical for higher-risk SaMD categories.